Capricor Therapeutics (CAPR) Net Equity Issued and Repurchased (2013 - 2025)
Capricor Therapeutics (CAPR) posted quarterly Net Equity Issued and Repurchased of $77.5 million for Q4 2025, down 4.13% year-over-year from $80.8 million in Q4 2024, and down 4.13% quarter-over-quarter from $80.8 million in Q4 2024.
Capricor Therapeutics (CAPR) Net Equity Issued and Repurchased (2013 - 2025) Analysis & Trends
Capricor Therapeutics' Net Equity Issued and Repurchased history runs 12 years deep, the most recent figure standing at $77.5 million for Q4 2025.
- In Q4 2025, Net Equity Issued and Repurchased fell 4.13% year-over-year to $77.5 million; the TTM figure through Dec 2025 stood at $175.3 million (up 75.12% YoY), while the FY2025 annual figure was $237.0 million, up 55.61% from the prior year.
- Net Equity Issued and Repurchased for Q4 2025 stood at $77.5 million, down from $80.8 million in the prior quarter.
- The five-year high for Net Equity Issued and Repurchased was $80.8 million in Q4 2024, with the low at $221081.0 in Q3 2023.
- The 5-year median for Net Equity Issued and Repurchased is $5.2 million (2021), against an average of $17.0 million.
- The sharpest annual moves came in 2021 and 2024: Net Equity Issued and Repurchased tumbled 96.53% in 2021, then surged 6684.84% in 2024.
- Capricor Therapeutics' Net Equity Issued and Repurchased stood at $7.5 million in 2021, then slumped by 61.02% to $2.9 million in 2022, then soared by 692.41% to $23.2 million in 2023, then jumped by 248.99% to $80.8 million in 2024, then fell by 4.13% to $77.5 million in 2025.
- Business Quant data shows CAPR's Net Equity Issued and Repurchased at $77.5 million in Q4 2025, $80.8 million in Q4 2024, and $15.0 million in Q3 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Equity Issued and Repurchased (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 49.20 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 141.90 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | Capricor Therapeutics | 383.47 Mn | 383.47 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 77.50 Mn |
| Dec 31, 2025 | 77.50 Mn |
| Dec 31, 2024 | 80.84 Mn |
| Dec 31, 2024 | 80.84 Mn |
| Sep 30, 2024 | 15.00 Mn |
| Sep 30, 2024 | 15.00 Mn |
| Jun 30, 2024 | 1.99 Mn |
| Jun 30, 2024 | 1.99 Mn |
| Mar 31, 2024 | 2.29 Mn |
| Mar 31, 2024 | 2.29 Mn |
| Dec 31, 2023 | 23.16 Mn |
| Dec 31, 2023 | 23.16 Mn |
| Sep 30, 2023 | 221,081.00 |
| Sep 30, 2023 | 221,081.00 |
| Jun 30, 2023 | 2.13 Mn |
| Jun 30, 2023 | 2.13 Mn |
| Dec 31, 2022 | 2.92 Mn |
| Dec 31, 2022 | 2.92 Mn |
| Sep 30, 2022 | 1.88 Mn |
| Sep 30, 2022 | 1.88 Mn |